Many botanical dietary supplements which carry label statements related to blood sugar management are available over the internet. Potential adulteration of such dietary supplements with anti-diabetic and other prescription drugs, some of which have been removed from the market due to adverse events, is of concern. In this study, we developed and validated an LC-MS/MS method to detect and quantitate fourteen anti-diabetic, two anti-obesity, and three cholesterol-lowering drugs in botanical dietary supplements sold for blood sugar management. Dietary supplements were extracted with methanol. No significant matrix effects were observed over a wide range of analyte concentrations. Mean recoveries of all 19 analytes from a<br/>single-product ranged from 88 to 113% at spike concentrations from 0.5 to 2000 µg/g. Mean recoveries of three analytes (metformin, phenformin, and sibutramine) from multiple-product composites ranged from 91 to 106% at a spike concentration of 100 µg/g. The relative standard deviations (RSDs, %) of intra-day analyses ranged from 0.2 to 13 for all recovery studies. Eighty botanical dietary supplements obtained in the U.S. and carrying label statements related to blood sugar management were analyzed using this method and none were found to be adulterated with the above 19 compounds. Two international products known to be adulterated were also analyzed by this method and found to contain the target analytes (phenformin, glibenclamide, and sibutramine). This method can be used to analyze dietary supplements for possible adulteration with these compounds.<br/>

Validation of an LC-MS/MS method for analysis of anti-diabetic, anti-obesity, and cholesterol-lowering drugs in botanical dietary supplements labelled for blood sugar management

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.